Genelux (GNLX) Expected to Announce Earnings on Monday

Genelux (NASDAQ:GNLX) is anticipated to announce its results before the market opens on Monday, April 6th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings results on Thursday, March 19th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.01 million for the quarter. On average, analysts expect Genelux to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Genelux Stock Performance

Shares of GNLX stock opened at $2.57 on Friday. Genelux has a 12-month low of $1.99 and a 12-month high of $8.53. The stock’s 50-day moving average price is $2.63 and its 200-day moving average price is $4.06. The stock has a market capitalization of $115.16 million, a price-to-earnings ratio of -2.99 and a beta of 0.47.

Wall Street Analysts Forecast Growth

GNLX has been the topic of a number of research analyst reports. Wall Street Zen raised Genelux from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Benchmark dropped their price objective on Genelux from $23.00 to $20.00 and set a “speculative buy” rating for the company in a research note on Friday, March 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genelux in a report on Thursday, January 22nd. Finally, HC Wainwright restated a “buy” rating on shares of Genelux in a report on Monday, January 5th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Genelux currently has an average rating of “Moderate Buy” and an average target price of $18.00.

Insider Activity at Genelux

In other news, Director John Thomas sold 10,000 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $2.90, for a total transaction of $29,000.00. Following the completion of the transaction, the director directly owned 482,784 shares of the company’s stock, valued at approximately $1,400,073.60. This represents a 2.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. raised its holdings in Genelux by 451.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 183,807 shares of the company’s stock worth $801,000 after purchasing an additional 150,463 shares during the last quarter. 683 Capital Management LLC purchased a new position in shares of Genelux in the fourth quarter valued at $572,000. Marshall Wace LLP raised its stake in shares of Genelux by 312.3% during the 4th quarter. Marshall Wace LLP now owns 139,148 shares of the company’s stock worth $607,000 after buying an additional 105,402 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Genelux during the 4th quarter worth $455,000. Finally, Osaic Holdings Inc. boosted its position in shares of Genelux by 1,911.4% in the 2nd quarter. Osaic Holdings Inc. now owns 105,016 shares of the company’s stock worth $301,000 after buying an additional 99,795 shares in the last quarter. 37.33% of the stock is owned by hedge funds and other institutional investors.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.